Tenmile

AdvanCell is a clinical-stage radiopharmaceutical company focused on developing innovative cancer therapies. The company specializes in alpha-emitting isotopes, specifically 212Pb, which are attached to molecules that target tumors directly. This approach allows for the delivery of cytotoxic radiation at the molecular level, addressing significant challenges in targeted alpha therapy regarding supply reliability and scalability. By providing safe and effective treatments for various forms of cancer, AdvanCell aims to establish its therapies as a standard of care in oncology.

Proton Intelligence is a Canadian company, founded in 2020 and based in Vancouver, that specializes in biomarker monitoring to assist in managing chronic diseases and improving patient outcomes. The company has developed a wearable continuous potassium monitoring platform aimed at individuals with hyperkalemia, particularly those suffering from chronic kidney disease and other co-morbidities. By providing accurate and real-time potassium measurements through interstitial fluid analysis, Proton Intelligence facilitates critical health monitoring for both clinicians and patients. This technology enables informed decision-making regarding medications, diet, and treatment options, thereby enhancing the management of hyperkalemia and promoting better overall health for affected individuals.

Psylo is a drug development company that specializes in next-generation psychedelics aimed at treating mental illness. The company focuses on creating novel therapeutics for psychiatric and neurological disorders, emphasizing non-hallucinogenic and rapid-acting agents. By leveraging psychedelic molecules, Psylo seeks to develop improved medications that provide effective alternatives to existing selective serotonin reuptake inhibitors (SSRIs). Its mission is to enhance treatment options for mood disorders, addiction, and certain neurological conditions, thereby broadening the scope of mental health care.

Operator of a cancer immunotherapy company intended to develop medicines to treat primary, recurrent and metastatic cancers. The company uses several different technologies and approaches utilizing viral vectors and affinity agents that can be conjugated to deliver biologicals, enabling doctors to utilize new and advanced treatments to cure patients even in advanced stages of cancer.

LimmaTech Biologics is a clinical-stage biotech company focused on developing vaccines to prevent life-threatening diseases. It specializes in creating bioconjugate vaccines through innovative techniques such as glycoengineering and protein glycosylation, which improve the efficiency of vaccine development and address challenges associated with traditional chemical conjugation methods. The company's proprietary self-adjuvanting and multi-antigen vaccine platforms target microbial infections that are increasingly resistant to existing treatments. LimmaTech Biologics is dedicated to expanding its pipeline, aiming to provide effective solutions for infectious diseases that currently have limited treatment options. Through its research and development efforts, the company seeks to enhance healthcare outcomes by delivering tailored vaccines for specific pathogens.

Tin Alley Ventures is a venture capital investment firm based in Melbourne, Australia, founded in 2022. The firm focuses on investing in technology startups at various stages, including seed, early, and later stages. It collaborates closely with companies and researchers within the University of Melbourne's ecosystem, aiming to support and develop businesses that have the potential to create significant social and economic impact. Through its strategic partnerships and investment approach, Tin Alley Ventures seeks to foster innovation and drive growth in the technology sector.

Carina Biotech is a biotechnology company focused on developing cellular immunotherapies, particularly for childhood and rare cancers. The company specializes in chimeric antigen receptor T cell (CAR-T) therapies aimed at treating solid tumors. By engineering patients' own immune systems to target and eliminate cancer cells, Carina Biotech's platform enhances the effectiveness of T cell therapy. Additionally, the company is dedicated to improving technologies that facilitate better access to solid tumors and optimize the manufacturing process of CAR-T cells, thereby broadening the potential for treatment across various cancer types.

Verge Genomics is a biotechnology company focused on transforming drug discovery for neurodegenerative diseases through the application of artificial intelligence. Founded by experts in machine learning and seasoned drug developers in neuroscience, the company aims to leverage advances in computational genomics and insights into brain science to identify promising therapeutic targets. Its drug discovery platform utilizes machine learning algorithms to analyze large datasets, enabling the identification of effective drugs and accelerating the development of life-saving treatments. By improving the efficiency of the drug development process, Verge Genomics seeks to enhance patient outcomes and reduce the overall costs associated with pharmaceutical development.

Emyria Limited is a healthcare technology and services company based in West Leederville, Australia, that operates a network of specialist medical clinics. These clinics provide treatments, including cannabinoid-based medicines, and are designed to enhance patient care through data-driven approaches. Founded in 2018, Emyria has established a partnership with Mind Medicine Australia to develop a clinical model for the safe provision of psychedelic-assisted therapies in the country. The company, formerly known as Emerald Clinics Limited, changed its name in September 2020, reflecting its broader focus on innovative treatment development and care delivery. As of mid-2020, Emyria operated four medical clinics dedicated to patient-centered care.

Mindset Health is a digital therapeutics company based in Melbourne, Victoria, founded in 2018 by Alex Naoumidis. The company focuses on helping individuals manage chronic health issues, particularly irritable bowel syndrome, anxiety, and chronic pain, through app-based hypnotherapy. Its platform provides treatment without necessitating dietary changes, enhancing sleep quality, and alleviating anxiety and stress. Mindset Health aims to offer a rapid, cost-effective, nonaddictive, and safe alternative for individuals seeking relief from these conditions, thereby improving overall well-being and quality of life.

SpeeDx is a company that specializes in molecular diagnostic solutions aimed at enhancing patient management through comprehensive information. Utilizing innovative real-time polymerase chain reaction (qPCR) technology, SpeeDx offers a leading portfolio of multiplex diagnostic tests. These tests are particularly focused on sexually transmitted infections (STIs), antibiotic resistance markers, and respiratory diseases. By employing advanced multiplex detection and priming strategies, SpeeDx enables healthcare providers to effectively diagnose infectious diseases and assess antibiotic resistance, ultimately improving clinical outcomes.

CurveBeam AI develops, manufactures, operates, and sells artificial intelligence tools for bone analysis.

Inventia Life Science Pty Ltd is an Australian company founded in 2013 and based in Alexandria. It specializes in 3D bioprinting technology aimed at enhancing cell-based research and clinical applications. The company develops, manufactures, and sells equipment, reagents, and bio-inks—both natural and synthetic—designed for advanced medical research. Inventia's innovative approach focuses on creating low-cost and standardized methods for producing three-dimensional human tissue and organ models. This technology is intended to accelerate cancer research, drug discovery, and advancements in regenerative medicine. By providing a comprehensive suite of hardware, software, consumables, and customized protocols, Inventia Life Science facilitates the flexible production of 3D cell-based assays, significantly impacting the medical research landscape.

Aravax is an early-stage biotechnology company based in Melbourne, Australia, dedicated to developing a safe and effective treatment for peanut allergies. Founded in May 2015 through the acquisition of intellectual property from Alfred Health and Monash University, Aravax employs proprietary technology aimed at resetting the immune system to tolerate peanuts without triggering allergic reactions. The company's innovative approach seeks to eliminate the risk of life-threatening responses to peanuts, allowing patients to undergo treatment and potentially overcome mild symptoms such as itchiness, rash, and gastrointestinal upset.

Perx Health is a digital care management program focused on enhancing treatment adherence for individuals with chronic conditions, including diabetes and behavioral health issues. The platform is specifically designed for clinically complex patients, employing various motivational techniques to engage users with low health literacy. By providing reminders, education, and monitoring of medication regimens, Perx Health effectively boosts adherence rates to 90% among high-risk members. The program incorporates elements of gamification, allowing users to earn rewards for adhering to their treatment schedules. Health plans utilizing Perx Health experience significant clinical improvements, such as better control of HbA1C and cholesterol levels, as well as substantial cost savings and a return on investment of 6-8 times per member.